

To: [redacted]@erasmusmc.nl; [redacted]@erasmusmc.nl; [redacted]@erasmusmc.nl; [redacted]@erasmusmc.nl; Minister van VWS; [redacted]@minvws.nl; [redacted]@lumc.nl; [redacted]@lumc.nl; [redacted]@vvd.nl; [redacted]@vvd.nl  
 From: [redacted]@radboudumc.nl  
 Sent: Tue 10/13/2020 8:21:14 AM  
 Subject: FW: ??: covid 19 inhibitors  
 Received: Tue 10/13/2020 8:21:27 AM  
[Screenshot 2020-10-13 at 10.15.45.png](#)

Goede morgen heren,


Chinezen reageren supersnel, wellicht dat ze COVID19 daarom snel onder controle krijgen.

Mvg

[redacted]

Dept of TumorImmunology,  
 RadboudUMC  
 Nijmegen  
 The Netherlands

[redacted]



From: [redacted] <[redacted]@shanghaitech.edu.cn>  
 Date: Tuesday, 13 October 2020 at 04:09  
 To: [redacted]@radboudumc.nl, "[redacted]@simmm.ac.cn" <[redacted]@simmm.ac.cn>, "[redacted]@mail.tsinghua.edu.cn" <[redacted]@mail.tsinghua.edu.cn>  
 Subject: [redacted] covid 19 inhibitors

Dear [redacted]

Thanks for your email. As you noted, both of ebiselen and DS are now applied orally. These two compounds have been approved to enter Phase II to treat COVID-19 by FDA. I am not so sure whether these two drug candidates can be developed as nebulizer (at least ebiselen is hardly soluble in water). But we will inform our collaborators whether this formulation is feasible for testing. Thanks again for your suggestion.

Best regards,

[redacted]

发件人: [redacted]@radboudumc.nl <[redacted]@radboudumc.nl>  
 发送时间: 2020年10月13日 1:53  
 收件人: [redacted]@shanghaitech.edu.cn; [redacted]@simmm.ac.cn; [redacted]@mail.tsinghua.edu.cn  
 主题: [redacted]

Dear [redacted]

I made a mistake. See red replacement.

I read with much interest your paper that appeared in Nature, Vol.582, 11June2020.

For Ebselen the the lowest IC50 was found. Ebselen is already tested in clinical trials. The medication was applied orally. Disulfiram is already used to inhibit **alcoholism**.

I wonder if Ebselen or Disulfiram could be nebulized to inhibit the virus when the virus is inhaled in the lung. This could decrease the enormous number of infectious virus and could save the patient from Intensive care treatment.

5.1.2e

Dept of TumorImmunology,  
RadboudUMC  
Nijmegen  
The Netherlands

*De informatie in dit bericht is uitsluitend bestemd voor de geadresseerde. Aan dit bericht en de bijlagen kunnen geen rechten worden ontleend. Heeft u deze e-mail onbedoeld ontvangen? Dan verzoeken wij u het te vernietigen en de afzender te informeren. Openbaar maken, kopiëren en verspreiden van deze e-mail of informatie uit deze e-mail is alleen toegestaan met voorafgaande schriftelijke toestemming van de afzender. Het Radboudumc staat geregistreerd bij de Kamer van Koophandel in het handelsregister onder nummer 41055629.*

*The content of this message is intended solely for the addressee. No rights can be derived from this message or its attachments. If you are not the intended recipient, we kindly request you to delete the message and inform the sender. It is strictly prohibited to disclose, copy or distribute this email or the information inside it, without a written consent from the sender. Radboud university medical center is registered with the Dutch Chamber of Commerce trade register with number 41055629.*